Published in J Mol Biol on August 05, 2005
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol (2007) 2.38
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
A decade of yeast surface display technology: where are we now? Comb Chem High Throughput Screen (2008) 1.37
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One (2008) 1.11
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun (2009) 1.02
Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Sci Transl Med (2014) 1.00
Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel (2010) 0.99
Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem (2012) 0.93
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther (2012) 0.92
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs (2014) 0.91
Slow, reversible, coupled folding and binding of the spectrin tetramerization domain. Biophys J (2012) 0.91
Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem (2011) 0.90
Improving the species cross-reactivity of an antibody using computational design. Bioorg Med Chem Lett (2009) 0.90
Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett (2014) 0.90
Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol (2010) 0.89
Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS One (2012) 0.89
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. J Virol (2015) 0.87
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron (2009) 0.87
Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem (2011) 0.85
Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol (2011) 0.85
A simple model for assessment of anti-toxin antibodies. Biomed Res Int (2013) 0.84
Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis (2016) 0.84
Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem (2012) 0.82
Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One (2015) 0.79
Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng (2011) 0.79
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel) (2015) 0.79
Arming Technology in Yeast-Novel Strategy for Whole-cell Biocatalyst and Protein Engineering. Biomolecules (2013) 0.79
Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS One (2016) 0.79
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs (2015) 0.78
High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One (2014) 0.78
TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res (2010) 0.76
Bi-epitope SPR surfaces: a solution to develop robust immunoassays. PLoS One (2014) 0.75
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One (2017) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Airway management for trauma patients with potential cervical spine injuries. Anesth Analg (1991) 4.38
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Conditions Affecting Enzyme Synthesis in Cotyledons of Germinating Seeds. Plant Physiol (1960) 3.69
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A (1991) 3.57
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol (1992) 3.19
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Inhibition by acetylene of conventional hydrogenase in nitrogen-fixing bacteria. Nature (1976) 3.11
Telling the truth about terminal cancer. JAMA (1998) 3.07
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Specific proteins mediate enhanced osteoblast adhesion on nanophase ceramics. J Biomed Mater Res (2000) 2.80
Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials (2000) 2.75
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Expression and biologic characterization of the murine chemokine KC. J Immunol (1995) 2.66
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol (1992) 2.43
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A (1998) 2.32
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
The role of female movement in the sexual behavior of Drosophila melanogaster. Behav Genet (1982) 2.21
Vacuum pack technique of temporary abdominal closure: a 7-year experience with 112 patients. J Trauma (2000) 2.13
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
Human anti-self antibodies with high specificity from phage display libraries. EMBO J (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Intracisternal A-particle genes in Mus musculus: a conserved family of retrovirus-like elements. Mol Cell Biol (1981) 2.07
Structural repertoire of the human VH segments. J Mol Biol (1992) 2.06
Osteoblast adhesion on nanophase ceramics. Biomaterials (1999) 2.02
Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology (1999) 2.02
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med (1998) 1.95
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol (1996) 1.90
Conditioned courtship in Drosophila and its mediation by association of chemical cues. Behav Genet (1983) 1.90
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Mechanisms of enhanced osteoblast adhesion on nanophase alumina involve vitronectin. Tissue Eng (2001) 1.86
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Reversible hypothyroidism in Addison's disease. Lancet (1972) 1.78
Impact of interruptions and distractions on dispensing errors in an ambulatory care pharmacy. Am J Health Syst Pharm (1999) 1.77
Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest (1990) 1.71
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71
Oral aspirin in postoperative pain: a quantitative systematic review. Pain (1999) 1.71
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis (1988) 1.65
Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med (2001) 1.63
Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61
Changes in lung function following the surgical treatment of bullous emphysema. Q J Med (1970) 1.61
Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol (2000) 1.60
Male courtship in Drosophila: the conditioned response to immature males and its genetic control. Genetics (1982) 1.60
Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol (2000) 1.60
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res (1998) 1.57
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun (1997) 1.56
Tumor targeting using anti-her2 immunoliposomes. J Control Release (2001) 1.56
The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54
Enhanced osteoclast-like cell functions on nanophase ceramics. Biomaterials (2001) 1.51
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain (2001) 1.51
The Relationship between Kappa and Paramecin in Paramecium Aurelia. Proc Natl Acad Sci U S A (1953) 1.51
Phase-specific genes for macroconidiation in Neurospora crassa. Genetics (1974) 1.50